What is it about?
In this commentary, published in Future Cardiology, I present the current evidence regarding the counterregulatory effects of PDE5 inhibitors on SARS-CoV-2 replication and COVID-19-associated thromboembolism. Given the recent findings regarding the pathogenesis of SARS-CoV-2, and the pathways involved in COVID-19, resulting in pulmonary fibrosis and thromboembolism; it appears that PDE5 inhibitors could be good candidates in the clinical management of COVID-19 patients, especially those with a history of underlying cardiac and metabolic diseases.
Featured Image
Photo by Fusion Medical Animation on Unsplash
Why is it important?
With their dual inhibitory effects on SARS-CoV-2 3CL pro and the NO/cGMP/PDE5 pathway, PDE5 inhibitors suggestively act in more than one way against COVID-19, leading to the inhibition of viral replication and downregulation of pro-inflammatory pathways concerned with the induction of iNOS and instigation of thromboembolism.
Perspectives
I am thrilled to have published this commentary in Future Cardiology.
Milad Shirvaliloo
Tabriz University of Medical Sciences
Read the Original
This page is a summary of: Targeting the SARS-CoV-2 3CL
pro
and NO/cGMP/PDE5 Pathway in COVID-19: A Commentary On PDE5 Inhibitors, Future Cardiology, February 2021, Taylor & Francis,
DOI: 10.2217/fca-2020-0201.
You can read the full text:
Resources
Contributors
The following have contributed to this page
